Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

NCT03398837 is registered in ClinicalTrials.gov with Corbus Pharmaceuticals Inc. as lead sponsor.

NCT NCT03398837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03398837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Lead sponsor
Corbus Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Terminated
Start date
December 18, 2017
Completion date
December 21, 2020
Enrollment
365 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse cutaneous systemic sclerosis